AstraZeneca

Open: 67.74 Close: 67.1 Change: -0.64

Our AI found some flaws in AstraZeneca.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, Astrazeneca, company, PLC, AZN, close, April, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Astrazeneca PLC ADR closed $9.46 below its 52-week high ($76.56) on April 25th. Q1 earnings are confirmed for Thursday, April 25, 2024. AstraZecas revenue was $44.35 billion, an increase of 18.53%.

Today's News

Astrazeneca reports positive data from phase ii trial of imfinzi. Trial of AstraZenecas Imfinzi regimen was carried out across 157 centres in 18 countries. AstraZeneca PLC ADR closed $9.46 below its 52-week high ($76.56), which the company achieved on April 25th. Astrazeneca (AZN) operates as a research-based biopharmaceutical company. AstraZeneca has 10 strategic partners and customers. The company recently partnered with Allorion Therapeutics. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK. AstraZecas sells its products through wholly-owned local marketing companies, distributors and local representative offices. Astrazeneca PLC (AZN) stock price, news, quote & history - Yahoo Finance. Markets closed S&P 500 4,890.97 -3.19 (-0.19%) Dow 30 38,109.43 +60.30 +0.30 (+0.16%) Nasdaq 15,455.36 -55.13 -0.36% Russell 2000 1,978!!! Our sustainable strategyamp Phen Avenysondriven weighted37undy antit AstraZeneca (NASDAQ: AZN) pay a dividend of $ 0.47 per share of Class A Common Stock. Q1 earnings are confirmed for Thursday, April 25, 2024. AstraZeneca PLC up 0.98% in premarket trading. AstraZecas revenue was $44.35 billion, an increase of 18.53% compared to the previous years $37.42 billion. Astrazeneca Plc pleaded guilty to criminal conspiracy and agreed to pay $355 million to settle U.S. fraud case. AstraZeneca and Sanofis RSV infant shots approved in China. Anglo-Swedish drugmaker buys Chinese cancer therapy firm Gracell.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, Astrazeneca, company, PLC, AZN, close, April, and the most common words in the summary are: astrazeneca, bloomberg, company, stock, news, see, subscribe, . One of the sentences in the summary was: Q1 earnings are confirmed for Thursday, April 25, 2024. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #bloomberg #company #stock #news #see #subscribe.